Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Lung cancer is the most common cause of cancer deaths worldwide. The two broad histological subtypes of lung cancer are small-cell lung cancer (SCLC), which is the cause of 15% of cases, and non-small-cell lung cancer (NSCLC), which accounts for 85% of cases and includes adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Although NSCLC and SCLC are commonly thought to be different diseases owing to their distinct biology and genomic abnormalities, the idea that these malignant disorders might share common cells of origin has been gaining support. This idea has been supported by the unexpected findings that a subset of NSCLCs with mutated EGFR return as SCLC when resistance to EGFR tyrosine kinase inhibitors develops. Additionally, other case reports have described the coexistence of NSCLC and SCLC, further challenging the commonly accepted view of their distinct lineages. Here, we summarise the published clinical observations and biology underlying tumours with combined SCLC and NSCLC histology and cancers that transform from adenocarcinoma to SCLC. We also discuss pre-clinical studies pointing to common potential cells of origin, and speculate how the distinct paths of differentiation are determined by the genomics of each disease.

[1]  J. Tomashefski,et al.  Mixed small cell and non-small cell lung cancer. , 1986, Chest.

[2]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[3]  M. Krasnow,et al.  Alveolar progenitor and stem cells in lung development, renewal and cancer , 2014, Nature.

[4]  P. Chuang,et al.  Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[5]  P. Nelson,et al.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. , 2010, The Journal of clinical investigation.

[6]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[7]  Y. P. Zhang,et al.  Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. , 2012, Neoplasma.

[8]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[9]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Nicholson,et al.  Non-small-cell lung cancer , 2011, The Lancet.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  A. Gemma,et al.  F1000 highlights , 2010 .

[13]  E. Thunnissen,et al.  A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Ou.  Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? , 2013, Journal of Clinical Pathology.

[15]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Liang Cheng,et al.  Small cell carcinoma of the urinary bladder. , 2010, Histology and histopathology.

[17]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[18]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[19]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[20]  I. Okamoto,et al.  Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. , 2005, Lung cancer.

[21]  M. Barbacid,et al.  Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[22]  E. Wijdicks,et al.  The Mayo Clinic experience , 2013, Practical Neurology.

[23]  R. Derynck,et al.  Impaired lung branching morphogenesis in the absence of functional EGF receptor. , 1997, Developmental biology.

[24]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Lim,et al.  Lung cancer in never-smokers , 2006, Journal of Clinical Pathology.

[26]  Nick Thatcher,et al.  Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Fukuoka,et al.  EGFR mutation in gefitinib-responsive small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Fukuoka,et al.  Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. , 2007, Lung cancer.

[29]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[30]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[31]  Kwok-Kin Wong,et al.  Characterization of the cell of origin for small cell lung cancer , 2011, Cell cycle.

[32]  P. Dartevelle,et al.  Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[34]  N. Choong,et al.  Small cell carcinoma of the urinary bladder , 2005, Cancer.

[35]  Yan Liu,et al.  EGFR Mutations are More Frequent in Well-Differentiated than in Poor-Differentiated Lung Adenocarcinomas , 2008, Pathology & Oncology Research.

[36]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[37]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[38]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[39]  J. Mendelsohn,et al.  Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. , 1987, Journal of the National Cancer Institute.

[40]  Jan P van Meerbeeck,et al.  Small-cell lung cancer , 1980, The Lancet.

[41]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[42]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[43]  K. Kasahara,et al.  Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. , 2013, Lung cancer.

[44]  N. Hanna,et al.  Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. , 2006, Lung cancer.

[45]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[46]  S. Ou,et al.  Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. , 2012, Clinical lung cancer.

[47]  P. Hasleton,et al.  Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. , 1986, British Journal of Cancer.

[48]  S. Digumarthy,et al.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[50]  Y. Yatabe,et al.  Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[51]  A. Berns,et al.  Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[52]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[53]  A. Nicholson,et al.  Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. , 2013, Lung cancer.

[54]  Yih-Leong Chang,et al.  Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[56]  R. Ueda,et al.  Significance of thymidylate synthase for resistance to pemetrexed in lung cancer , 2010, Cancer science.

[57]  K. Wikenheiser-Brokamp.  Rb family proteins differentially regulate distinct cell lineages during epithelial development , 2004, Development.

[58]  T. Shibata,et al.  Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung , 2007, Cancer science.

[59]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[60]  M. Ladanyi,et al.  EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.

[61]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[62]  C. Rudin,et al.  Small Cell Lung Cancer , 2022 .

[63]  Shan-Mei Xu,et al.  Alveolar Type II Cells Possess the Capability of Initiating Lung Tumor Development , 2012, PloS one.

[64]  J. Hainsworth,et al.  Combined small-cell and non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[66]  A. Berns,et al.  Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. , 2011, Cancer cell.

[67]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[68]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.